Search results
AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030
The Wall Street Journal· 7 days agolongest-serving chief executive, Pascal Soriot, has no plans to step down for now as the company...
ASCO24: Tagrisso in the spotlight, Caribou’s adjustment and Lilly’s KRAS competitor
BioPharma Dive via Yahoo Finance· 4 days agoAstraZeneca’s therapy could see wider use after ASCO data. Elsewhere, Caribou sought to explain an...
3 No-Brainer Stocks to Buy in June | The Motley Fool
The Motley Fool· 5 days agoYou're probably familiar with the old adage, "April showers bring May flowers." Here's why they picked AbbVie (ABBV 3.15%), AstraZeneca (AZN 1.63%), and...
3 No-Brainer Stocks to Buy in June
Motley Fool via Yahoo Finance· 5 days agoBut what does June bring? Three Motley Fool contributors think the new month should usher in great investing opportunities. Here's why they picked AbbVie...
ASCO 2024: What's New in Breast Cancer Research?
Medscape· 1 day agoDrs Alexandra Thomas and Virginia Kaklamani discuss highlights in breast cancer research from the ASCO 2024 Annual Meeting.
New antibiotic based on AstraZeneca drugs kills off deadly bacteria, spares the good guys
FierceBiotech· 7 days agoA new antibiotic based on drugs developed by AstraZeneca can kill off dangerous bacteria that cause...
Antibody-Drug Conjugate Picks Up Another Win in HR+/HER2-low Breast Cancer
MedPage Today· 5 days agoThe antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) significantly improved...
AstraZeneca’s breast cancer trial shows ‘unprecedented’ results | Honolulu Star-Advertiser
Honolulu Star-Advertiser· 5 days agoAstraZeneca and Daiichi Sankyo’s Enhertu slows the progression of breast cancer by about five months...
Veeva R&D Summit: Pharma companies need a say in AI regulation
Clinical Trials Arena via Yahoo Finance· 1 day agoSenderovitz is working with partners from other pharmaceutical companies, including James...
Women denied ‘wonder drug’ that could double terminal breast cancer life expectancy
Daily Telegraph· 4 days agoWomen with HER2-low or ultra-low breast cancer who took Enhertu lived without their cancer growing...